Eli Lilly has escalated enforcement of its 340B claims data policy, issuing an ultimatum to hospitals that have not complied with requests to share data intended to show they are not double-dipping discounts. In the provided items, Lilly is reported to have given select hospitals five days to comply or face the risk of losing 340B discounts. Hospitals reportedly argue they need government intervention and continued guidance, framing the dispute as a compliance and data-sharing impasse rather than an isolated billing issue. For manufacturers and 340B stakeholders, the episode signals that payor-contract enforcement and claims verification will remain a high-intensity area—especially for large branded portfolios under 340B contracts.